CTLA4 and renal cell carcinoma: Patients received anti-PD-1, anti-CTLA-4 or interferon alpha-2b therapy for either metastatic or unresectable melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), or neuroendocrine tumors (NET).